Value Collaborative Videos

PhRMA

On November 14, 2017, RealClearPolitics—in partnership with The Value Collaborative—brought together a cross-section of experts to examine the biopharmaceutical supply chain. Panelists explained the distinct roles that make up the supply chain, analyzed the factors that contribute to the price consumers pay for their medicines and identified steps that can be taken to bring greater value to consumers.

Speakers:

  • Adam Fein, president, Pembroke Consulting
  • Doug Hoey, CEO, National Community Pharmacists Association
  • Cheryl Larson, incoming president, Midwest Business Group on Health
  • Mark Merritt, president and CEO, Pharmaceutical Care Management Association
  • Lori Reilly, executive vice president for policy, research and membership, PhRMA
  • Jim Sheninger, chief pharmacy officer, GoodRx
  • Senator Steve Sweeney, president, New Jersey State Senate

Moderators:

  • Tom Bevan, co-founder and publisher, RealClearPolitics
  • Tony Mills, editor, RealClearPolicy
  • Erin Waters, president, RealClear Media Group

Today’s breakthrough medicines have transformed how we treat and cure some of the most complex diseases facing patients. Unfortunately, patients often have to fight to access these innovative treatments. In response to this issue, the movement toward a system that focuses on value and outcomes for patients has gained even more momentum in recent years.

On September 19, 2017, The Value Collaborative partnered with Bloomberg to convene CEOs, experts and thought leaders to discuss how stakeholders are working together across the health care ecosystem to unlock and support value in the future of health care. Panelists at the event talked about how groups are working together to better define value, what steps need to be taken to create an infrastructure that can support a value-driven system and what is currently being done to ensure that the movement toward better value for patients and the system continues amidst a changing policy landscape.

Speakers:

  • Amy Abernethy, chief medical officer, chief scientific officer & senior vice president, oncology, Flatiron Health
  • Delos M. Cosgrove, CEO and president, Cleveland Clinic
  • Joaquin Duato, executive vice president and chairman, pharmaceuticals, Johnson & Johnson
  • Mark McClellan, Robert J. Margolis professor of business, medicine and policy and director, Duke-Margolis Center for Health Policy at Duke University
  • Harold L. Paz, executive vice president and chief medical officer, Aetna
  • Stefano Pessina, executive vice chairman and CEO, Walgreens Boots Alliance
  • Ian C. Read, chairman of the board & CEO, Pfizer
  • Gary M. Reedy, CEO, American Cancer Society, Inc.
  • Stephen J. Ubl, president and CEO, PhRMA

Moderators:

  • Drew Armstrong, health care reporter, Bloomberg
  • Anna Edney, health regulation report, Bloomberg
  • David Gura, anchor, television and radio, Bloomberg

On August 21-24, the Precision Medicine Leaders Summit convened key thought leaders from government, academia, the biopharmaceutical industry and the payer and provider communities to discuss advancing the precision medicine field.

At the conference, The Value Collaborative sponsored a panel of distinguished leaders from the diagnostic, academic and patient communities. The discussion, Paying for Personalized Value: New Models for New Science, focused on how to best assess and pay for value in the era of personalized medicine to ensure savings for the health care system as a whole and improved care, outcomes and access for patients.

Speakers:

  • Jerry Conway, vice president, Reimbursement & Payer Strategy, Foundation Medicine
  • Andrea Ferris, president and chairman of the board, LUNGevity Foundation
  • James C. Robinson, Ph.D., director, Berkeley Center for Health Technology, University of California—Berkley

Moderator:

  • Gretta Stone, deputy vice president, policy & research, Pharmaceutical Research and Manufacturers of America (PhRMA)

On June 29, 2017, the Turning the Tide Against Cancer National Conference convened leaders from across the oncology community to explore the role of the patient across the continuum of cancer research and care and identify strategies that policymakers might consider implementing to support meaningful patient engagement and deliver value to patients.

At the conference, The Value Collaborative sponsored a panel on Partnering to Deliver High-Value Care for Patients, to examine how health care stakeholders are partnering on innovative approaches to support the delivery of high-value care. The discussion brought together executives from industry and non-profit sectors, and focused on why partnerships deliver better value for patients, which collaborative strategies improve value, and how other executives can operationalize similar strategies to support high quality patient care.

Speakers:

  • David Lansky, Ph.D., president and CEO, Pacific Business Group on Health
  • J. Leonard Lichtenfeld, M.D., deputy CMO, American Cancer Society
  • Bill Martin, vice president/general manager, Accredo Commercial and Trade Relations, Express Scripts
  • Lori M. Reilly, Esq., executive vice president, Policy, Research & Membership, PhRMA
  • Stephen J. Ubl, president and CEO, Pharmaceutical Research and Manufacturers of America (PhRMA)

Moderator:

  • Susan Dentzer, president and CEO, Network for Excellence in Health Innovation

The rapidly changing health care landscape in the United States is witnessing a transition from a volume-based to a value-based reimbursement structure. In the process, patient care is also changing.

What steps are biopharmaceutical companies, insurers, and providers taking to create a more value-driven health care system? Is there a role that policymakers can or should play to ensure that this approach improves outcomes and what are the implications for patients?

On June, 13, 2017, The Hill convened policymakers, health industry representatives, and patient advocates for a conversation about the impact of outcomes-based care. 

Speakers:

  • Senator Bill Cassidy (R-LA), member, Senate Committee on Health, Education, Labor & Pensions 
  • Congresswoman Doris Matsui (D-CA), member, House Energy and Commerce Committee
  • Liz Fowler, vice president, Global Health Policy, Johnson & Johnson
  • Patrick Geraghty, CEO, GuideWell and Florida Blue
  • Marilyn Serafini, health care policy consultant
  • Pamela Sutton-Wallace, CEO, University of Virginia Medical Center
  • Stephen J. Ubl, president and CEO, PhRMA
  • Cynthia Zagieboylo, president and CEO, National Multiple Sclerosis Society

Moderators:

  • Bob Cusack, editor-in-chief, The Hill
  • Kim Dixon, policy editor, The Hill

Across the health care system there is a movement to better pay for services based on outcomes, and industry leaders are increasingly coalescing around private market solutions that produce and reward better value for patients.

On February 23, 2017, The Value Collaborative partnered with Morning Consult to convene representatives from the payer, provider and patient communities to discuss new innovative ways to pay for medicines and the policy solutions needed to advance value-driven health care.

Speakers:

  • Marc Boutin, JD, CEO, National Health Council
  • Tanisha Carino Ph.D., vice president, U.S. Public Policy, GlaxoSmithKline
  • Patricia J. Goldsmith, CEO, CancerCare
  • Clifford A. Hudis, MD, CEO, American Society of Clinical Oncology
  • Samuel Nussbaum, MD, senior fellow, USC Schaeffer Center & former CMO, Anthem Inc.
  • Stephen J. Ubl, president and CEO, Pharmaceutical Research and Manufacturers of America (PhRMA)

Moderator:

  • Michael Ramlet, co-founder & CEO, Morning Consult